about
Recent Transmission Clustering of HIV-1 C and CRF17_BF Strains Characterized by NNRTI-Related Mutations among Newly Diagnosed Men in Central ItalyCharacterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naïve to the antiretroviral drugs.Characterization of drug-resistance mutations in HIV type 1 isolates from drug-naive and ARV-treated patients in Bulgaria.Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypesIncomplete APOBEC3G/F Neutralization by HIV-1 Vif Mutants Facilitates the Genetic Evolution from CCR5 to CXCR4 Usage.Early antiretroviral treatment (eART) limits viral diversity over time in a long-term HIV viral suppressed perinatally infected child.Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy.Impact of HIV-1 tropism on the emergence of non-AIDS events in HIV-infected patients receiving fully suppressive antiretroviral therapy.Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev.Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study groupMolecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase.Impact of pre-therapy viral load on virological response to modern first-line HAART.The Role of HIV Infection in Neurologic Injury.Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029.Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens.Comparative Evaluation of Subtyping Tools for Surveillance of Newly Emerging HIV-1 Strains.The HIV-1 reverse transcriptase polymorphism A98S improves the response to tenofovir disoproxil fumarate+emtricitabine-containing HAART both in vivo and in vitro.Multiple Hepatitis B Virus (HBV) Quasispecies and Immune-Escape Mutations Are Present in HBV Surface Antigen and Reverse Transcriptase of Patients With Acute Hepatitis B.A recent epidemiological cluster of acute hepatitis B genotype F1b infection in a restricted geographical area of Italy.Reliable timescale inference of HBV genotype A origin and phylodynamics.HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia.Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection.Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression.Effects of Amprenavir on HIV-1 Maturation, Production and Infectivity Following Drug Withdrawal in Chronically-Infected Monocytes/Macrophages.Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels.Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens.Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia.Detecting and understanding genetic and structural features in HIV-1 B subtype V3 underlying HIV-1 co-receptor usage.The multifactorial pathways towards resistance to the cytosine analogues emtricitabine and lamivudine: evidences from literature.Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice.Excretion of the novel polyomaviruses KI and WU in the stool of patients with hematological disorders.Genetic diversity of HIV type 1 in Montenegro.Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen.Non-B HIV type 1 subtypes among men who have sex with men in Rome, Italy.Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine.Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage.Epidemiological network analysis in HIV-1 B infected patients diagnosed in Italy between 2000 and 2008.Population dynamics of HIV-1 subtype B in a cohort of men-having-sex-with-men in Rome, Italy.'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing.Genetic divergence of HIV-1 B subtype in Italy over the years 2003-2016 and impact on CTL escape prevalence
P50
Q28547222-3F81AD20-1DCC-40ED-8086-58AF276CE9C1Q33483060-621D4643-E756-40A5-A66B-A0EE0AD96484Q34083250-E0871675-B3B1-45A7-859B-6374E0B46219Q34563005-E0EE1C3C-637A-40F9-9412-26533D018E05Q35859926-496D4314-07A2-40FD-A004-3FCF42DD75FDQ36219112-61552A09-DFB0-40E2-BDCC-15294B9F4E4DQ36250342-E6B1CDD7-B836-4A77-903E-BAD80C0E7577Q37077610-C69E1D59-460B-466C-8891-9D37EC69A02CQ37247695-689CF614-108C-4EA1-BA5A-F28F4D91200BQ37530942-836EEB5A-536C-4B0F-9A2B-448BF89BD7F3Q37835977-F2B64D87-BD2D-415D-B951-B170F61373E6Q38427973-0B072B2C-8CA6-46AB-BD93-381901FE9F01Q39224160-DCF6A267-49BE-438A-818E-B09F4794C28DQ39499575-5AB13007-EA08-4C88-8586-36D11A9E7CB7Q39648233-D62FC52F-7427-42C8-B8DF-4AE7DC52ABD5Q40137561-6198A8B9-10A5-480E-BF6C-43C5C072C75CQ40573390-420C30AE-0943-469F-B4CB-2C0524752FFCQ40779997-A07B6339-1DAF-4E6A-B34D-DD1D2CD0B2D6Q41059975-A303AB65-73E5-43BF-A059-88CC282B566DQ41200056-5AE02EDD-AF69-449C-8DC5-F972BFA07F07Q41465991-8DAA4F6C-6C3D-4E44-B0F7-794F8260A019Q41632541-774A7F8E-62CB-4C51-9813-B06914517A1AQ41651814-59DADA9B-7453-4D91-A39F-DF66087DA3E0Q41928771-47876489-C722-4119-A1FB-AEB45C8C88DBQ42243024-1BD9F936-8F22-41D3-929F-DB770A216E07Q42925586-ED2D6928-B80B-4661-8FF7-FD3F715A3AE6Q42973710-AB7FCE69-8D49-4028-8783-00B7D14A00F8Q43246211-1E9E5793-099A-41DD-9D0A-2FFB2104C33BQ43875709-5C7322C1-8F0A-4466-BCBE-13CFB782CE71Q44047772-FDF82CFF-5742-47FB-90B8-2CEAB567DF97Q45147355-86B39D7F-257D-4C52-B588-0EF31B55BC9BQ45222313-BCDCF53A-3D76-41DD-BBD5-571AAFED6EECQ45720065-EBDFADD2-6516-4E6D-80C4-68E7CB0CEC8DQ46128525-068F96E9-172A-4213-A352-C1D97125B1E9Q46230871-D65D8666-77E2-4207-9127-B0D831E8BD88Q48054995-5F365374-847F-4B6C-A811-9ABB18B2614CQ51606809-B6C1F0B5-8024-4092-8B28-9CB6066FB690Q51671977-04E9716C-9B75-4F46-9470-97631A4B1A5CQ54563317-46108987-DC35-473D-BDF4-416F57147995Q57794708-F9D90AE6-DEA1-40E4-8F65-E9CF3000BBB2
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Claudia Alteri
@ast
Claudia Alteri
@en
Claudia Alteri
@es
Claudia Alteri
@nl
Claudia Alteri
@sl
type
label
Claudia Alteri
@ast
Claudia Alteri
@en
Claudia Alteri
@es
Claudia Alteri
@nl
Claudia Alteri
@sl
prefLabel
Claudia Alteri
@ast
Claudia Alteri
@en
Claudia Alteri
@es
Claudia Alteri
@nl
Claudia Alteri
@sl
P1053
J-9116-2016
P106
P1153
24824156300
P21
P31
P3829
P496
0000-0003-4270-5079